Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Feb 26;2(2):CD008455.
doi: 10.1002/14651858.CD008455.pub2.

Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ)

Victoria Rollason  1 , Alexandra Laverrière, Laura C I MacDonald, Tanya Walsh, Martin R Tramèr, Nicole B Vogt-Ferrier
Affiliations

Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ)

Victoria Rollason et al. Cochrane Database Syst Rev. .

Abstract

Background: Bisphosphonate drugs can be used to prevent and treat osteoporosis and to reduce symptoms and complications of metastatic bone disease; however, they are associated with a rare but serious adverse event: osteonecrosis of the maxillary and mandibular bones. This condition is called bisphosphonate-related osteonecrosis of the jaw or BRONJ. BRONJ is diagnosed when people who are taking, or have previously taken, bisphosphonates have exposed bone in the jaw area for more than eight weeks in the absence of radiation treatment. There is currently no "gold standard" of treatment for BRONJ. The three broad categories of intervention are conservative approaches (e.g. mouth rinse, antibiotics), surgical interventions and adjuvant non-surgical strategies (e.g. hyperbaric oxygen therapy, platelet-rich plasma), which can be used in combination.

Objectives: To determine the efficacy and safety of any intervention aimed at treating BRONJ.

Search methods: We searched the following databases to 15 December 2015: the Cochrane Oral Health Group Trials Register, the Cochrane Breast Cancer Group Trials Register (20 September 2011), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE via Ovid, EMBASE via Ovid, CancerLit via PubMed, CINAHL via EBSCO and AMED via Ovid. We scanned the references cited in retrieved articles and contacted experts in the field, the first authors of included papers, study sponsors, other bisphosphonates investigators and pharmaceutical companies. We searched for ongoing trials through contact with trialists and by searching the US National Institutes of Health Trials Register (clinicaltrials.gov) and the World Health Organization Clinical Trials Registry Platform. We also conducted a grey literature search to September 2015.

Selection criteria: Randomised controlled trials (RCTs) comparing the effects of any treatment for BRONJ with another treatment or placebo.

Data collection and analysis: Two review authors independently screened the search results, assessed the risk of bias in the included trials and extracted data. When in dispute, we consulted a third review author.

Main results: One small trial at high risk of bias met the inclusion criteria. The trial randomised 49 participants, most of whom had cancer. It compared standard care (defined as surgery, antibiotics and oral rinses at the discretion of the oral-maxillofacial surgeon) to standard care plus hyperbaric oxygen therapy (2 atmospheres twice a day for 40 treatments). The trial measured the percentage of participants who improved or healed at three, six, 12 and 18 months and last contact. It also measured mean weekly pain scores.At three months, the study found that the participants in intervention group were more likely to have an improvement in their osteonecrosis than the standard care group participants (risk ratio (RR) 1.94, 95% confidence interval (CI) 1.01 to 3.74). There was no clear difference between the groups for the outcome 'healed' at three months (RR 3.60, 95% CI 0.87 to 14.82). There was no clear difference between the groups for improvement or healing when they were evaluated at six, 12 and 18 months and last contact.The study did not give any information on adverse events.Although the findings suggest adjunctive hyperbaric oxygen improved BRONJ, the quality of the evidence is very low since the only study was underpowered and was at high risk of bias due to lack of blinding, cross-over of participants between groups and very high attrition (50% at 12 months and 80% at 18 months in this study, which was designed for an intended follow-up of 24 months).

Authors' conclusions: There is a lack of evidence from randomised controlled trials to guide treatment of bisphosphonate-related osteonecrosis of the jaw (BRONJ). One small trial at high risk of bias evaluated hyperbaric oxygen therapy (HBO) as an adjunct to "standard" care and could not confirm or refute the effectiveness of HBO. There are two ongoing trials of teriparatide treatment for BRONJ. We found no randomised controlled trials of any other BRONJ treatments. High quality randomised controlled trials are needed. We provide recommendations for their focus and design.

PubMed Disclaimer

Conflict of interest statement

Victoria Rollason: none known. Alexandra Laverrière: none known. Laura MacDonald: none known. Tanya Walsh: none known. Martin Tramèr: none known. Nicole B Vogt‐Ferrier: none known.

Figures

1
1
Study flow diagram.
See this image and copyright information in PMC

Comment in

References

References to studies included in this review

Freiberger 2012 {published data only (unpublished sought but not used)}
    1. Freiberger JJ, Padilla‐Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate‐related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery 2012;70:1573‐83. [PUBMED: 22698292] - PubMed

References to studies excluded from this review

Atalay 2011 {published data only}
    1. Atalay B, Yalcin S, Emes Y, Aktas I, Aybar B, Issever H, et al. Bisphosphonate‐related osteonecrosis: laser‐assisted surgical treatment or conventional surgery?. Lasers in Medical Science 2011;26:815‐23. - PubMed
Gasparini 2010 {published data only}
    1. Gasparini G, Saponaro G, Nardo F, Moro A, Boniello R, Cervelli D, et al. Clinical experience with spiramycin in bisphosphonate‐associated osteonecrosis of the jaw. International Journal of Immunopathology and Pharmacology 2010;23(2):619‐26. - PubMed
Graziani 2012 {published data only}
    1. Graziani F, Vescovi P, Campisi G, Favia G, Gabriele M, Gaeta GM, et al. Resective surgical approach shows a high performance in the management of advanced cases of bisphosphonate‐related osteonecrosis of the jaws: a retrospective survey of 347 cases. Journal of Oral and Maxillofacial Surgery 2012;70:2501‐7. - PubMed
Kim 2014 {published data only}
    1. Kim KM, Park W, Oh SY, Kim HJ, Nam W, Lim SK, et al. Distinctive role of 6‐month teriparatide treatment on intractable bisphosphonate‐related osteonecrosis of the jaw. Osteoporosis International 2014;25:1625‐32. - PubMed
Lee 2014 {published data only}
    1. Lee LW, Hsiao SH, Chen LK. Clinical treatment outcomes for 40 patients with bisphosphonates‐related osteonecrosis of the jaws. Journal of the Formosan Medical Association 2014;113:166‐72. - PubMed
Manfredi 2011 {published data only}
    1. Manfredi M, Merigo E, Guidotti R, Meleti M, Vescovi P. Bisphosphonate‐related osteonecrosis of the jaws: a case series of 25 patients affected by osteoporosis. International Journal of Oral and Maxillofacial Surgery 2011;40:277‐84. - PubMed
Pelaz 2014 {published data only}
    1. Pelaz A, Junquera L, Gallego L, García‐Consuegra L, Junquera S, Gómez C. Alternative treatments for oral bisphosphonate‐related osteonecrosis of the jaws: a pilot study comparing fibrin rich in growth factors and teriparatide. Medicina Oral, Patologia Oral y Cirugia Bucal 2014;19(4):e320‐6. - PMC - PubMed
Vescovi 2007 {published data only}
    1. Vescovi P, Merigo E, Meleti M, Fornaini C, Nammour S, Manfredi M. Nd:YAG laser biostimulation of bisphosphonate‐associated necrosis of the jawbone with and without surgical treatment. British Journal of Oral and Maxillofacial Surgery 2007;45:628‐32. - PubMed
Vescovi 2010 {published data only}
    1. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, et al. Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in Medical Science 2010;25:101‐13. - PubMed
Vescovi 2012a {published data only}
    1. Vescovi P, Manfredi M, Merigo E, Guidotti R, Meleti M, Pedrazzi G, et al. Early surgical laser‐assisted management of bisphosphonate‐related osteonecrosis of the jaws (BRONJ): a retrospective analysis of 101 treated sites with long‐term follow‐up. Photomedicine and Laser Surgery 2012;30(1):5‐13. - PubMed
Vescovi 2012b {published data only}
    1. Vescovi P, Manfredi M, Merigo E, Meleti M, Guidotti R, Sarraj A. Bisphosphonate‐associated osteonecrosis of the jaws: treatment and long‐term follow‐up in 160 patients [Osteonecrosi dei mascellari e bifosfonati: terapia e follow‐up a lungo termine in 160 pazienti]. Dental Cadmos 2012;80((1)):9‐21.
Vescovi 2014 {published data only}
    1. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S, et al. Conservative surgical management of stage I bisphosphonate‐related osteonecrosis of the jaw. International Journal of Dentistry 2014;2014. [DOI: 10.1155/2014/107690] - DOI - PMC - PubMed

References to ongoing studies

Additional references

AAOMS 2014
    1. Ruggiero S, Dodson T, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. Medication‐related osteonecrosis of the jaw ‐ 2014 update. http://www.aaoms.org/images/uploads/pdfs/mronj_position_paper.pdf (accessed 14 December 2015). - PubMed
Azarpazhooh 2008
    1. Azarpazhooh A, Limeback H. The application of ozone in dentistry: a systematic review of literature. Journal of Dentistry 2008;36:104‐16. - PubMed
Bocci 2004
    1. Bocci V. Ozone as Janus: this controversial gas can be either toxic or medically useful. Mediators of Inflammation 2004;13(1):3‐11. - PMC - PubMed
Capsoni 2006
    1. Capsoni F, Longhi M, Weinstein R. Bisphosphonate‐associated osteonecrosis of the jaw: the rheumatologist's role. Arthritis Research Therapy 2006;8(5):219. - PMC - PubMed
Coulthard 2014
    1. Coulthard P, Bailey E, Esposito M, Furness S, Renton TF, Worthington HV. Surgical techniques for the removal of mandibular wisdom teeth. Cochrane Database of Systematic Reviews 2014, Issue 7. [DOI: 10.1002/14651858.CD004345.pub2] - DOI - PubMed
Dayisoylu 2013
    1. Dayisoylu EH, Şenel FÇ, Üngör C, Tosun E, Çankaya M, Ersöz S, et al. The effects of adjunctive parathyroid hormone injection on bisphosphonate‐related osteonecrosis of the jaws: an animal study. International Journal of Oral Maxillofacial Surgery 2013;42(11):1475‐80. - PubMed
Delanian 1999
    1. Delanian S, Balla‐Mekias S, Lefaix JL. Striking regression of chronic radiotherapy damage in a clinical trial of combined pentoxifylline and tocopherol. Journal of Clinical Oncology 1999;17(10):3283‐90. - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ 1997;315:629‐34. - PMC - PubMed
Fernandez 2012
    1. Fernandez R, Griffiths R. Water for wound cleansing. Cochrane Database of Systematic Reviews 2012, Issue 2. [DOI: 10.1002/14651858.CD003861.pub3] - DOI - PubMed
Fliefel 2015
    1. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate‐related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. International Journal of Oral Maxillofacial Surgery 2015;44(5):568‐85. - PubMed
GRADE 2004
    1. The GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490. - PMC - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration 2011. Available from www.cochrane‐handbook.org.
Jull 2015
    1. Jull AB, Cullum N, Dumville JC, Westby MJ, Deshpande S, Walker N. Honey as a topical treatment for wounds. Cochrane Database of Systematic Reviews 2015, Issue 3. [DOI: 10.1002/14651858.CD005083.pub4] - DOI - PMC - PubMed
Khan 2008
    1. Khan AA, Sandor GK, Dore E, Morrison AD, Alsahli M, Amin F, et al. Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw. Journal of Rheumatology 2008;35:1391‐7. - PubMed
Khan 2015
    1. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O'Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal of Bone and Mineral Research 2015;30(1):3‐23. - PubMed
Khosla 2007
    1. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, et al. Bisphosphonate‐associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research 2007;22:1479‐91. - PubMed
Lai 2015
    1. Lai LP, Stitik TP, Foye PM, Georgy JS, Patibanda V, Chen B. Use of platelet rich plasma in intra‐articular knee injections for osteoarthritis: a systematic review. PM R: Journal of Injury, Function, and Rehabilitation 2015;7(6):637‐48. - PubMed
Longo 2014
    1. Longo F, Guida A, Aversa C, Pavone E, Costanzo G, Ramaglia L, et al. Platelet rich plasma in the treatment of bisphosphonate‐related osteonecrosis of the jaw: personal experience and review of the literature. International Journal of Dentistry 2014;2014:298945. [DOI: 10.1155/2014/298945] - DOI - PMC - PubMed
Marx 2003
    1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery 2003;61(9):1115‐7. - PubMed
Migliorati 2006
    1. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate‐associated osteonecrosis: a long‐term complication of bisphosphonate treatment. Lancet Oncology 2006;7(6):508‐14. - PubMed
Moghadam 2001
    1. Moghadam HG, Urist MR, Sandor GKB, Clokie CML. Successful mandibular reconstruction using a BMP bioimplant. Journal of Craniofacial Surgery 2001;12(2):119‐27. - PubMed
MRHA 2006
    1. Commission on Human Medicines, Medicines and Healthcare Products Regulatory Agency (MHRA). Osteonecrosis of the jaw with bisphosphonates. Current Problems in Pharmacovigilance 2006;31:4‐5.
Neiburger 1999
    1. Neiburger EJ. Rapid healing of gingival incisions by the helium‐neon diode laser. Journal of Massachusetts Dental Society 1999;48(1):8‐13, 40. - PubMed
Page 2014
    1. Page MJ, Green S, Kramer S, Johnston RV, McBain B, Buchbinder R. Electrotherapy modalities for adhesive capsulitis (frozen shoulder). Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: 10.1002/14651858.CD011324] - DOI - PMC - PubMed
Pautke 2009
    1. Pautke C, Bauer F, Tischer T, Kreutzer K, Weitz J, Kesting M, et al. Fluorescence‐guided bone resection in bisphosphonate‐associated osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery 2009;67(3):471‐6. - PubMed
Pazianas 2007
    1. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clinical Therapeutics 2007;29:1548‐58. - PubMed
Petticrew 2013
    1. Petticrew M, Anderson L, Elder R, Grimshaw J, Hopkins D, Hahn R, et al. Complex interventions and their implications for systematic reviews: a pragmatic approach. Journal of Clinical Epidemiology 2013;66(11):1209‐14. - PubMed
Raje 2008
    1. Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clinical Cancer Research 2008;14(8):2387‐95. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ripamonti 2012
    1. Ripamonti CI, Maniezzo M, Pessi MA, Boldini S. Treatment of osteonecrosis of the jaw (ONJ) by medical ozone gaz insufflation. A case report. Tumori 2012;98:e72‐5. - PubMed
Ruggeiro 2007
    1. Ruggeiro SL. Guidelines for the diagnosis of bisphosphonate‐related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral Bone Metabolism 2007;4(1):37‐42. - PMC - PubMed
Ruggiero 2004
    1. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery 2004;62(5):527‐34. - PubMed
Ruggiero 2009
    1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate‐related osteonecrosis of the jaws ‐ 2009 update. Journal of Oral and Maxillofacial Surgery 2009;67(5 Suppl):2‐12. - PubMed
Rupel 2014
    1. Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical approaches in bisphosphonates‐related osteonecrosis of the jaw (BRONJ). Oral Oncology 2014;50(11):1049‐57. - PubMed
Rücker 2008
    1. Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statistics in Medicine 2008;27(5):746‐63. - PubMed
Saini 2011
    1. Saini R. Ozone therapy in dentistry: a strategic review. Journal of Natural Science, Biology and Medicine 2011;2(2):151‐3. - PMC - PubMed
SDCEP 2011
    1. Scottish Dental Clinical Effectiveness Programme. Oral health management of patients prescribed bisphosphonates dental clinical guideline, 2011. www.sdcep.org.uk/wp‐content/uploads/2013/03/SDCEP+Bisphosphonates+Guidan... (accessed 22 February 2016).
Silva 2016
    1. Silva LF, Curra C, Munerato MS, Deantoni CC, Matsumoto MA, Cardoso CL, et al. Surgical management of bisphosphonate‐related osteonecrosis of the jaws: literature review. Oral and Maxillofacial Surgery 2016;20(1):1‐17. - PubMed
Solomon 2013
    1. Solomon DH, Mercer E, Woo SB, Avorn J, Schneeweiss S, Treister N. Defining the epidemiology of bisphosphonate‐associated osteonecrosis of the jaw: prior work and current challenges. Osteoporosis International 2013;24(1):237‐44. - PubMed
Spanou 2015
    1. Spanou A, Lyritis GP, Chronopoulos E, Tournis S. Management of bisphosphonate‐related osteonecrosis of the jaw: a literature review. Oral Diseases 2015;21(8):927‐36. - PubMed
Stevenson 2005
    1. Stevenson M, Jones ML, Nigris E, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technology Assessment 2005;9(22):1‐160. - PubMed
Walter 2008
    1. Walter C, Al‐Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate‐associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. European Urology 2008;54(5):1066‐72. - PubMed
Wells 2008a
    1. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004523.pub3] - DOI - PubMed
Wells 2008b
    1. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD003376.pub3] - DOI - PMC - PubMed
Wells 2008c
    1. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Welch V, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD001155.pub2] - DOI - PubMed
Wikesjö 2009
    1. Wikesjö UM, Qahash M, Huang YH, Xiropaidis A, Polimeni G, Susin C. Bone morphogenetic proteins for periodontal and alveolar indications; biological observations ‐ clinical implications. Orthodontics & Craniofacial Research 2009;12(3):263‐70. - PubMed
Woo 2006
    1. Woo SB, Hellstein JW, Kalmar JR. Narrative (corrected) review: bisphosphonates and osteonecrosis of the jaws. Annals of Internal Medicine 2006;144(10):753‐61. - PubMed
Worthington 2015
    1. Worthington H, Clarkson J, Weldon J. Priority oral health research identification for clinical decision‐making. Evidence‐based Dentistry 2015;16(3):69‐71. - PubMed

References to other published versions of this review

Vogt‐Ferrier 2010
    1. Vogt‐Ferrier NB, Hugentobler M, Uebelhart B, Tramèr M, Rollason V. Interventions for treating osteonecrosis of the jaw associated with bisphosphonates. Cochrane Database of Systematic Reviews 2010, Issue 4. [DOI: 10.1002/14651858.CD008455] - DOI

Publication types

MeSH terms

LinkOut - more resources